Overexpression of α-Synuclein Decreased Viability and Enhanced Sensitivity to Prostaglandin E2, Hydrogen Peroxide, and a Nitric Oxide Donor in Differentiated Neuroblastoma Cells

Journal of Neuroscience Research

Volumn 76, Issue 3, 2004, Pages 415-422

  Prasad, Judith E ^a   Kumar, Bipin ^a   Andreatta, Cynthia ^a   Nahreini, Piruz ^a   Hanson, Amy J ^a   Yan, Xiang Dong ^a   Prasad, Kedar N ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

synuclein; Alzheimer's disease; Differentiated neuroblastoma cells; Hydrogen peroxide; Nitrous oxide donor; Parkinson's disease; Prostaglandin E2

Indexed keywords

ALPHA SYNUCLEIN; HYDROGEN PEROXIDE; LINSIDOMINE; MESSENGER RNA; NEUROTOXIN; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEASOME; RETROVIRUS VECTOR;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEGENERATIVE DISEASE; MOUSE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; CELL DIFFERENTIATION; CELL SURVIVAL; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; MICE; MOLSIDOMINE; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NITRIC OXIDE DONORS; SYNUCLEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 2342650150     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20058     Document Type: Article

References (37)

1. Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E, Marambaud P. 2000. Role of the proteasome in Alzheimer's disease. Biochim Biophys Acta 1502:133-138.
2. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55.
3. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R. 2002. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 99:14524-14529.
4. Duda JE, Shah U, Arnold SE, Lee VM, Trojanowski JQ. 1999. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 160:515-522.
5. el-Agnaf OM, Irvine GB. 2002. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans 30:559-565.
6. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
7. Hanson AJ, Prasad JE, Nahreini P, Andreatta C, Kumar B, Yan XD, Prasad KN. 2003. The overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide and nitric oxide) in differentiated neuroblastoma cells. J Neurosci Res 74:148-159.
8. Hashimoto M, Masliah E. 1999. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 9:707-720.
9. Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, Kittel A, Saitoh T, Miller A, Masliah E. 1997. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237:611-616.
10. Hovland AR, Nahreini P, Andreatta CP, Edwards-Prasad J, Prasad KN. 2001. Identifying genes involved in regulating differentiation of neuroblastoma cells. J Neurosci Res 64:302-310.
11. Koppal T, Drake J, Yatin S. 1998. Peroxynitrite-mediated damage to brain membrane proteins and lipids: another oxidative pathway for membrane alterations in Alzheimer's disease (AD). Soc Neurosci 24:1217a.
12. Kotzbauer PT, Trojanowsk JQ, Lee VM. 2001. Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17:225-232.
13. Kruger R, Muller T, Riess O. 2000. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders. J Neural Transm 107:31-40.
14. Kumar B, Andreatta C, Koustas WT, Cole WC, Edwards-Prasad J, Prasad KN. 2002. Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J Neurosci Res 68:627-635.
15. Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. 2003. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 4:97-112.
16. Lee SJ. 2003. Alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Antioxid Redox Signal 5:337-348.
17. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. 1999. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45:353-357.
18. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. 2002. alpha-Synudeinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99:10813-10818.
19. Lucking CB, Brice A. 2000. Alpha-synuclein and Parkinson's disease. Cell Mol Life Sci 57:1894-1908.
20. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. 2003. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23:3095-3099.
21. Miller AD, Rosman GJ. 1989. Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980-990.
22. Nahreini P, Hovland AR, Kumar B, Andreatta C, Edwards-Prasad J, Prasad KN. 2001. Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells. Cell Mol Neurobiol 21:65-79.
23. Nahreini P, Andreatta C, Kumar B, Hanson A, Edwards-Prasad J, Freed CR, Prasad KN. 2003. Distinct patterns of gene expression induced by viral oncogenes in human embryonic brain cells. Cell Mol Neurobiol 23:27-42.
24. Neve RL, McPhie DL, Chen Y. 2001. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? Biochem Soc Symp 67:37-50.
25. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90:8392-8396.
26. Prasad KN. 1991. Differentiation of neuroblastoma cells: a useful model for neurobiology and cancer. Biol Rev Camb Philos Soc 66:431-451.
27. Prasad KN, Mandal B, Waymire JC, Lees GJ, Vernadakis A, Weiner N. 1973. Basal level of neurotransmitter synthesizing enzymes and effect of cyclic AMP agents on the morphological differentiation of isolated neuroblastoma clones. Nat New Biol 241:117-119.
28. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. 1999. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 96:7797-7802.
29. Rockwell P, Yuan H, Magnusson R, Figueiredo-Pereira ME. 2000. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 374:325-333.
30. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
31. Sharma SK, Ebadi M. 2003. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid Redox Signal 5:251-264.
32. Suh YH, Checler F. 2002. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54:469-525.
33. Tabner BJ, Turnbull S, El-Agnaf OM, Allsop D. 2002. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32:1076-1083.
34. Yankner BA, Mesulam MM. 1991. Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med 325:1849-1857.
35. Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Ueda K, Cheder F, Kuroda S. 2002. NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases. Acta Neuropathol (Berl) 104:637-648.
36. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. 2000. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866:33-43.
37. Zhou W, Schaack J, Zawada WM, Freed CR. 2002. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res 926:42-50.